Skip to content

Study · Animal study (in vivo) · rat · 2017

8 results

Erythropoietin-Derived Peptide Protects Against Acute Lung Injury After Rat Traumatic Brain Injury.

Liu Y, Lu J, Wang X, Chen L, Liu S, Zhang Z, Yao W

Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology14 Apr 2017Cited by 9 (Europe PMC)

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In rats with traumatic brain injury, pHBSP treatment decreased lung wet/dry ratios at 8 h and 24 h post-injury.

    In plain wordsIn rats with brain injury, treatment with this peptide reduced lung swelling (wet/dry ratio) at 8 and 24 hours.

    Outcome
    DecreaseLung wet/dry ratio (pulmonary edema) at 8 h and 24 h post-TBI
    Study

    ratn: not reported in source

    weight-drop induced traumatic brain injury model
    Outcome group
    Inflammation markers · Respiratory
    Studied dose
    Dose not stated

    Source sentences

    Summary
    At 8 h and 24 h post-TBI, pHBSP treatment significantly decreased wet/dry ratios, decreased total BALF protein, and attenuated the histological signs of pulmonary injury.
    1 context sentence
    Summary · context
    In this study, we studied the effect of pHBSP on TBI-caused ALI by using a weight-drop induced TBI model.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In rats with traumatic brain injury, pHBSP treatment decreased total protein in bronchoalveolar lavage fluid at 8 h and 24 h post-injury.

    In plain wordsIn rats with brain injury, treatment with this peptide lowered protein in lung wash fluid at 8 and 24 hours.

    Outcome
    DecreaseTotal BALF protein at 8 h and 24 h post-TBI
    Study

    ratn: not reported in source

    weight-drop induced traumatic brain injury model
    Outcome group
    Inflammation markers · Respiratory
    Studied dose
    Dose not stated

    Source sentences

    Summary
    At 8 h and 24 h post-TBI, pHBSP treatment significantly decreased wet/dry ratios, decreased total BALF protein, and attenuated the histological signs of pulmonary injury.
    1 context sentence
    Summary · context
    In this study, we studied the effect of pHBSP on TBI-caused ALI by using a weight-drop induced TBI model.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In rats with traumatic brain injury, pHBSP treatment attenuated the histological signs of lung injury at 8 h and 24 h post-injury.

    In plain wordsIn rats with brain injury, treatment with this peptide reduced the signs of lung damage seen under the microscope.

    Outcome
    DecreaseHistological signs of pulmonary injury at 8 h and 24 h post-TBI
    Study

    ratn: not reported in source

    weight-drop induced traumatic brain injury model
    Outcome group
    Inflammation markers · Respiratory
    Studied dose
    Dose not stated

    Source sentences

    Summary
    At 8 h and 24 h post-TBI, pHBSP treatment significantly decreased wet/dry ratios, decreased total BALF protein, and attenuated the histological signs of pulmonary injury.
    1 context sentence
    Summary · context
    In this study, we studied the effect of pHBSP on TBI-caused ALI by using a weight-drop induced TBI model.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In rats with traumatic brain injury, pHBSP treatment decreased the accumulation of CD68+ macrophages in the lung at 24 h.

    In plain wordsIn rats with brain injury, treatment with this peptide reduced immune cell (macrophage) build-up in the lung at 24 hours.

    Outcome
    DecreaseCD68+ macrophage accumulation in lung at 24 h post-TBI
    Study

    ratn: not reported in source

    weight-drop induced traumatic brain injury model
    Outcome group
    Inflammation markers · Respiratory
    Studied dose
    Dose not stated

    Source sentences

    Summary
    At 24 h post-TBI, pHBSP treatment decreased the accumulation of CD68+ macrophages in the lung and reduced the mRNA levels of TNF-α, IL-6, IL-1β and iNOS in the lung.
    1 context sentence
    Summary · context
    In this study, we studied the effect of pHBSP on TBI-caused ALI by using a weight-drop induced TBI model.
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In rats with traumatic brain injury, pHBSP treatment reduced lung TNF-α mRNA levels at 24 h.

    In plain wordsIn rats with brain injury, treatment with this peptide lowered lung TNF-α, an inflammation signal, at 24 hours.

    Outcome
    DecreaseLung TNF-α mRNA level at 24 h post-TBI
    Study

    ratn: not reported in source

    weight-drop induced traumatic brain injury model
    Outcome group
    Inflammation markers · Respiratory
    Studied dose
    Dose not stated

    Source sentences

    Summary
    At 24 h post-TBI, pHBSP treatment decreased the accumulation of CD68+ macrophages in the lung and reduced the mRNA levels of TNF-α, IL-6, IL-1β and iNOS in the lung.
    1 context sentence
    Summary · context
    In this study, we studied the effect of pHBSP on TBI-caused ALI by using a weight-drop induced TBI model.
  6. 06AnimalAnimal study (in vivo)Efficacy outcome

    In rats with traumatic brain injury, pHBSP treatment reduced lung IL-6 mRNA levels at 24 h.

    In plain wordsIn rats with brain injury, treatment with this peptide lowered lung IL-6, an inflammation signal, at 24 hours.

    Outcome
    DecreaseLung IL-6 mRNA level at 24 h post-TBI
    Study

    ratn: not reported in source

    weight-drop induced traumatic brain injury model
    Outcome group
    Inflammation markers · Respiratory
    Studied dose
    Dose not stated

    Source sentences

    Summary
    At 24 h post-TBI, pHBSP treatment decreased the accumulation of CD68+ macrophages in the lung and reduced the mRNA levels of TNF-α, IL-6, IL-1β and iNOS in the lung.
    1 context sentence
    Summary · context
    In this study, we studied the effect of pHBSP on TBI-caused ALI by using a weight-drop induced TBI model.
  7. 07AnimalAnimal study (in vivo)Efficacy outcome

    In rats with traumatic brain injury, pHBSP treatment reduced lung IL-1β mRNA levels at 24 h.

    In plain wordsIn rats with brain injury, treatment with this peptide lowered lung IL-1β, an inflammation signal, at 24 hours.

    Outcome
    DecreaseLung IL-1β mRNA level at 24 h post-TBI
    Study

    ratn: not reported in source

    weight-drop induced traumatic brain injury model
    Outcome group
    Inflammation markers · Respiratory
    Studied dose
    Dose not stated

    Source sentences

    Summary
    At 24 h post-TBI, pHBSP treatment decreased the accumulation of CD68+ macrophages in the lung and reduced the mRNA levels of TNF-α, IL-6, IL-1β and iNOS in the lung.
    1 context sentence
    Summary · context
    In this study, we studied the effect of pHBSP on TBI-caused ALI by using a weight-drop induced TBI model.
  8. 08AnimalAnimal study (in vivo)Efficacy outcome

    In rats with traumatic brain injury, pHBSP treatment reduced lung iNOS mRNA levels at 24 h.

    In plain wordsIn rats with brain injury, treatment with this peptide lowered lung iNOS, an inflammation-related enzyme signal, at 24 hours.

    Outcome
    DecreaseLung iNOS mRNA level at 24 h post-TBI
    Study

    ratn: not reported in source

    weight-drop induced traumatic brain injury model
    Outcome group
    Inflammation markers · Respiratory
    Studied dose
    Dose not stated

    Source sentences

    Summary
    At 24 h post-TBI, pHBSP treatment decreased the accumulation of CD68+ macrophages in the lung and reduced the mRNA levels of TNF-α, IL-6, IL-1β and iNOS in the lung.
    1 context sentence
    Summary · context
    In this study, we studied the effect of pHBSP on TBI-caused ALI by using a weight-drop induced TBI model.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    9 Oct 2026, 19:08 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:13 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.